Valuation: NetraMark Holdings Inc.

Market Cap 73.81M 52.38M 45.97M 42.81M 39.37M 5B 75.08M 508M 199M 2.48B 197M 192M 8.57B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 73.81M 52.38M 45.97M 42.81M 39.37M 5B 75.08M 508M 199M 2.48B 197M 192M 8.57B EV / Sales 2026 *
184x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 46.66M
+1.09%-1.11%-23.25%+16.25% 2,890B
-6.08%-6.88%-21.76%+593.60% 315B
-9.11%-16.45%+147.53%+945.22% 115B
+1.80%+0.02%+3.28%+47.17% 93.39B
-0.39%-1.53%+66.40%+123.62% 89.65B
-1.33%-1.35%-35.23%-14.88% 74.48B
+2.89%+1.08%-33.18%+68.57% 63.94B
+1.50%+4.95%+9.52%+63.34% 45.29B
+2.23%-5.71%-59.08%+27.15% 34.67B
Average -0.28%-2.47%+6.03%+207.78% 413.59B
Weighted average by Cap. -0.04%-1.52%-15.36%+98.20%

Financials

2026 *2027 *
Net sales 401K 285K 250K 233K 214K 27.18M 408K 2.76M 1.08M 13.48M 1.07M 1.05M 46.58M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise